Search: WFRF:(Kowey Peter R) >
Impact of dronedaro...
Impact of dronedarone on patients with atrial fibrillation and diabetes : A sub-analysis of the ATHENA and EURIDIS/ADONIS studies
-
- Handelsman, Yehuda (author)
- Metabolic Institute of America
-
- Bunch, T. Jared (author)
- University of Utah
-
- Rodbard, Helena W. (author)
- Endocrine and Metabolic Consultants
-
show more...
-
- Steinberg, Benjamin A. (author)
- University of Utah
-
- Thind, Munveer (author)
- Lankenau Institute for Medical Research
-
- Bigot, Gregory (author)
- IVIDATA
-
- Konigsberg, Lana (author)
- Sanofi US Services Inc.
-
- Wieloch, Mattias (author)
- Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups,Sanofi S.A., France
-
- Kowey, Peter R. (author)
- Lankenau Institute for Medical Research
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2022
- 2022
- English.
-
In: Journal of Diabetes and its Complications. - : Elsevier BV. - 1056-8727. ; 36:7
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Aim: This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes. Methods: Patients were categorized according to baseline diabetes status. Time-to-event analyses were performed using Kaplan-Meier method. Hazard-ratios were assessed using Cox models. Results: 945/4628 (dronedarone = 482; placebo = 463) patients in ATHENA and 215/1237 (dronedarone = 148; placebo = 67) patients in EURIDIS/ADONIS studies had diabetes. In ATHENA, there were higher rates of CV hospitalization/death in patients with diabetes (39.5%) than without diabetes (34.7%). Incidence of first CV hospitalization/death was lower in patients with diabetes treated with dronedarone (35.1%) than placebo (44.1%), and time to this event was longer in those treated with dronedarone than placebo (log-rank p = 0.005). Median AF/AFL recurrence time was longer in patients treated with dronedarone than placebo in patients with diabetes (ATHENA: 722 vs 527 days, log-rank p = 0.004; EURIDIS/ADONIS: 100 vs 23 days, log-rank p = 0.15) or without diabetes (ATHENA: 741 vs 492 days, log-rank p < 0.0001; EURIDIS/ADONIS: 120 vs 59 days, log-rank p = 0.0002). Occurrence of any treatment-related adverse events with dronedarone was similar for patients with/without diabetes and was comparable to placebo. Conclusions: Dronedarone reduced incidence of CV hospitalization/death, AF/AFL recurrence and increased time to these events in AF/AFL patients with/without diabetes. Trial registration: Not applicable, as it was a post hoc analysis. This article is based on previously conducted studies (ATHENA: NCT00174785, EURIDIS: NCT00259428, and ADONIS: NCT00259376).
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- Anti-arrhythmic drug
- Atrial fibrillation
- Atrial flutter
- Cardiovascular disease
- Diabetes
- Dronedarone
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database